Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04038359
Title A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)
Acronym TEMPO
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Verastem, Inc.
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | DEU

No variant requirements are available.